Advertisement


Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, on Results from NSABP B-36 and SOFT Trials

2014 San Antonio Breast Cancer Symposium

Advertisement

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.



Related Videos

Breast Cancer

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, Discuss the SOFT Trial

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.

Breast Cancer

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:

  • The TNT trial comparing docetaxel to carboplatin
  • The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
  • Pembrolizumab in a phase Ib study

Breast Cancer

Charles E. Geyer, Jr, MD, FACP, on the NSABP B-36 Trial

Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses findings from abstract S3-02, “NSABP B-36: A randomized phase III trial comparing six cycles of fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer.”

Breast Cancer

Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses abstract S2-02, “The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with estrogen receptor–positive, aromatase inhibitor–resistant advanced or metastatic breast cancer: Part I results.”

Breast Cancer

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial."

Advertisement

Advertisement



Advertisement